Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin.
Karen D CorbinSamuel Dagogo-JackChristopher P CannonDavid Z I CherneyFrancesco CosentinoRobert FrederichJie LiuAnnpey PongJianxin LinNilo B CaterRichard E PratleyPublished in: Diabetes, obesity & metabolism (2022)
NCT01986881 This article is protected by copyright. All rights reserved.